Amalgamated Bank lowered its stake in shares of INC Research Holdings, Inc. (NASDAQ:INCR) by 0.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,071 shares of the company’s stock after selling 15 shares during the period. Amalgamated Bank’s holdings in INC Research Holdings were worth $233,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in INCR. Vanguard Group Inc. raised its stake in shares of INC Research Holdings by 6.8% in the first quarter. Vanguard Group Inc. now owns 6,044,044 shares of the company’s stock valued at $277,119,000 after buying an additional 386,699 shares during the period. BlackRock Inc. increased its position in INC Research Holdings by 40,517.6% in the first quarter. BlackRock Inc. now owns 3,544,294 shares of the company’s stock valued at $162,506,000 after buying an additional 3,535,568 shares in the last quarter. Mackenzie Financial Corp increased its position in INC Research Holdings by 93.1% in the first quarter. Mackenzie Financial Corp now owns 1,196,849 shares of the company’s stock valued at $54,876,000 after buying an additional 577,034 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in INC Research Holdings during the first quarter valued at $37,634,000. Finally, Marshall Wace North America L.P. acquired a new position in INC Research Holdings during the first quarter valued at $37,634,000. Institutional investors own 99.84% of the company’s stock.

Shares of INC Research Holdings, Inc. (NASDAQ INCR) traded up 0.63% on Friday, hitting $56.00. 645,386 shares of the company were exchanged. INC Research Holdings, Inc. has a 52-week low of $40.65 and a 52-week high of $61.10. The firm has a market cap of $3.03 billion, a P/E ratio of 34.31 and a beta of 1.42. The company has a 50-day moving average price of $56.38 and a 200 day moving average price of $52.08.

INC Research Holdings (NASDAQ:INCR) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. INC Research Holdings had a return on equity of 40.69% and a net margin of 5.69%. The company had revenue of $258.10 million during the quarter, compared to analyst estimates of $256.76 million. During the same period in the previous year, the company earned $0.61 earnings per share. The company’s quarterly revenue was down .3% compared to the same quarter last year. Analysts predict that INC Research Holdings, Inc. will post $2.61 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “INC Research Holdings, Inc. (NASDAQ:INCR) Shares Sold by Amalgamated Bank” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/19/inc-research-holdings-inc-nasdaqincr-position-reduced-by-amalgamated-bank-updated-updated-updated.html.

INCR has been the topic of several research reports. Zacks Investment Research raised shares of INC Research Holdings from a “sell” rating to a “hold” rating in a research note on Friday, May 5th. Wells Fargo & Company downgraded shares of INC Research Holdings from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 3rd. BidaskClub downgraded shares of INC Research Holdings from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Jefferies Group LLC reaffirmed a “hold” rating and set a $62.50 target price on shares of INC Research Holdings in a research note on Sunday, July 30th. Finally, KeyCorp raised shares of INC Research Holdings from a “sector weight” rating to an “overweight” rating and set a $68.00 target price on the stock in a research note on Monday, June 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. INC Research Holdings presently has an average rating of “Hold” and an average price target of $63.79.

In other news, CEO Alistair Macdonald sold 10,555 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $58.38, for a total transaction of $616,200.90. Following the sale, the chief executive officer now directly owns 83,935 shares in the company, valued at $4,900,125.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Christopher L. Gaenzle sold 6,873 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $58.32, for a total value of $400,833.36. Following the sale, the chief accounting officer now owns 47,450 shares in the company, valued at $2,767,284. The disclosure for this sale can be found here. 0.24% of the stock is owned by insiders.

About INC Research Holdings

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Institutional Ownership by Quarter for INC Research Holdings (NASDAQ:INCR)

Receive News & Stock Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related stocks with our FREE daily email newsletter.